Girard Gibbs announces class action lawsuit on behalf of investors of Immunomedics

03-03-2014 Business Wire HealthComments (0)

BiotechnologyImmunomedicsPharmaceuticalUSA

Girard Gibbs LLP announces that a class action lawsuit has been filed on behalf of purchasers of Immunomedics, Inc. (NASDAQ: IMMU) common stock between May 9, 2013 and October 9, 2013, inclusive, who are seeking to recover damages for alleged violations of the Securities Exchange Act of 1934. Immunomedics is a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top